LAUNCH SALE ENDS OCTOBER 1, 2025
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
+1 518-558-4528
+1 833-933-2106
+1 833-933-2106
support@over40alphacoffeeshop.com
LAUNCH SALE ENDS OCTOBER 1, 2025
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
FREE SHIPPING ON USA SUPPLEMENT ORDERS OVER $75USD
FREE SHIPPING ON INTL SUPPLEMENT ORDERS OVER $150USD
+1 518-558-4528
+1 833-933-2106
+1 833-933-2106
support@over40alphacoffeeshop.com
Retatrutide is an investigational once weekly medication developed by Eli Lilly that activates three hormone receptors involved in appetite, blood sugar and energy metabolism: GLP 1, GIP and glucagon. In Lilly’s Phase 3 TRIUMPH 1 trial, the highest studied dose produced an average 28.3% weight reduction at 80 weeks, but retatrutide remains investigational and is not yet FDA approved.
The information in this article is provided for educational and informational purposes only and should not be considered medical advice, diagnosis, treatment, or a recommendation to use retatrutide or any other medication, peptide, research compound, dose, protocol, or combination. Retatrutide remains an investigational drug and has not been approved by the FDA for weight loss, obesity, diabetes, or any other indication. Some information discussed below comes from controlled pharmaceutical clinical trials, while other information comes from research peptide reference materials and should not be treated as equivalent. Always discuss medications, weight management and peptide based therapies with a qualified licensed healthcare professional who understands your medical history, medications, blood work and individual risk factors.
Funk Roberts explores the potential of Redditrutide, a promising peptide for obesity and metabolic health, discussing recent clinical trial results, mechanisms, and personal insights.
00:00 Introduction to Retatrutide and its potential
02:12 The triple receptor activation: GIP, GLP1, and glucagon
04:38 Implications of the phase three trial outcomes
05:45 Upcoming studies and head-to-head trials
06:48Why Funk Roberts is excited about Retatrutide
08:42 Caution: Retatrutide is investigational and not FDA approved
09:39 Muscle preservation and healthy aging strategies
10:44 Final thoughts: science, hype, and informed decisions
11:32 Market availability and future prospects
12:11Conclusion and next steps for interested individuals
Retatrutide, also known by its development name LY3437943, is an experimental medication being developed by Eli Lilly primarily for obesity and related metabolic diseases.
If you’ve already heard about Ozempic, Wegovy, Mounjaro or Zepbound, understanding retatrutide becomes much easier.
Think about your metabolism as having several different switches that control things such as hunger, fullness, blood sugar and how your body handles energy.
Semaglutide primarily flips one switch: GLP 1.
Tirzepatide flips two switches: GLP 1 + GIP.
Retatrutide is designed to flip three switches: GLP 1 + GIP + glucagon.
That’s why scientists call retatrutide a triple hormone receptor agonist.
This three pathway approach is what makes retatrutide so interesting. Researchers are essentially asking whether controlling appetite and glucose metabolism while simultaneously influencing energy metabolism can produce even greater improvements in obesity and metabolic health.
And the results so far have attracted enormous attention.
However, there’s something I want you to remember throughout this article:
Retatrutide is still experimental.
It isn’t simply a newer version of Ozempic that has already been approved for public use.
Let’s make this really simple.
Your body naturally produces hormones that communicate with your brain, stomach, pancreas, liver and other tissues.
You can think of these hormones as messengers.
One messenger might tell your brain:
“You’ve eaten enough.”
Another helps your body respond appropriately to the food you’ve eaten.
Another influences how your body manages stored energy.
Retatrutide is designed to imitate signals from three of these metabolic systems at the same time.
The first pathway is GLP 1, which stands for glucagon like peptide 1.
Don’t worry about remembering the name.
Remember what it does.
GLP 1 helps regulate appetite and increases feelings of fullness after eating. It also influences gastric emptying and helps your pancreas release insulin appropriately when blood sugar rises.
In simple English:
GLP 1 can help you feel satisfied eating less food.
This is the primary pathway targeted by semaglutide.
The second pathway is GIP, or glucose dependent insulinotropic polypeptide.
GIP is another hormone released in response to eating. It participates in insulin secretion and energy metabolism and interacts with GLP 1 signaling in ways that researchers believe contribute to the effectiveness of dual agonists such as tirzepatide.
You don’t need to memorize all the physiology.
Think:
GLP 1 + GIP work together to influence hunger, blood sugar and how your body responds to food.
Now we get to the part that makes retatrutide different.
Glucagon.
Glucagon is commonly taught as the hormone that helps prevent your blood sugar from falling too low by signaling your liver to make stored energy available.
But glucagon biology goes beyond blood sugar.
Glucagon receptor activation can also influence energy expenditure and lipid metabolism. The idea behind retatrutide’s triple agonist design is therefore not simply to make you eat less, but potentially to influence both sides of energy balance.
Think about it this way:
Put those three signals into one molecule, and you begin to understand why researchers are so interested in retatrutide.
This doesn’t mean glucagon magically “melts fat.” The actual human effects come from the interaction of all three pathways and remain an active area of research.
CLICK HERE AND GET 15% OFF YOUR PEPTIDES WHEN YOU USE CODE: FUNK15
The most obvious potential benefit is substantial weight loss, but that’s not the entire story.
Retatrutide is interesting because obesity isn’t simply an appearance problem. Excess body fat, particularly visceral and ectopic fat, is connected with insulin resistance, type 2 diabetes, fatty liver disease, cardiovascular disease, sleep apnea and other health problems.
For a man over 40, the real goal shouldn’t simply be:
“How much lighter can I become?”
The better question is:
“Can I reduce excess body fat while improving my metabolic health and protecting my muscle?”
That distinction matters.
Weight reduction is where Retatrutide has produced its most headline grabbing results.
The original Phase 2 obesity trial involved 338 adults. At 48 weeks, participants receiving 12 mg had an average weight reduction of 24.2%, compared with 2.1% with placebo.
Those results were impressive.
Then came Phase 3.
In TRIUMPH 1, participants receiving 12 mg averaged 28.3% weight reduction at 80 weeks.
We’ll dig into those numbers shortly.
Because Retatrutide activates GLP 1 and GIP pathways, it can influence appetite, fullness and food intake.
For someone who has spent years fighting hunger while trying to maintain a calorie deficit, that could be extremely important.
But appetite suppression creates another issue for men over 40:
You still need to eat enough protein and nutrients.
Eating dramatically less food while neglecting resistance training and protein isn’t the transformation strategy I want for men over 40.
Retatrutide is also being studied in people with type 2 diabetes.
Phase 2 research demonstrated meaningful reductions in HbA1c along with substantial body weight reduction, which is why Lilly has continued studying the compound across obesity and diabetes populations.
TRIUMPH 1 also found greater improvements than placebo in several cardiometabolic measures, including blood pressure, triglycerides, non HDL cholesterol, inflammation measured by hsCRP and glycemic measures.
That is an important part of the conversation.
Losing weight is useful.
Improving health is the bigger goal.
TRIUMPH 1 also reported meaningful reductions in waist circumference. That matters because your waist gives us information that the bathroom scale cannot.
For men over 40, carrying excessive abdominal and visceral fat is much more than a cosmetic issue.
However, I wouldn’t call retatrutide a “visceral fat destroying peptide.” That’s marketing language, not the way we should interpret clinical science.
Retatrutide is being investigated primarily as a treatment for obesity and overweight with related health complications, as well as type 2 diabetes.
Lilly’s broader development program is also investigating outcomes related to cardiovascular and kidney health. For example, the ongoing TRIUMPH Outcomes study is evaluating once weekly retatrutide for cardiovascular and kidney outcomes in adults living with obesity.
The key word throughout this section is studied.
Being investigated for a condition does not mean a medication has already been proven and approved to treat that condition
This is where Retatrutide becomes especially interesting.
We now have meaningful human data from both Phase 2 and Phase 3 research.
The landmark Phase 2 trial published in the New England Journal of Medicine included 338 adults with obesity or overweight plus a weight related condition.
Participants received different doses of retatrutide or placebo once weekly for 48 weeks.
At 48 weeks, average weight reductions were:
compared with 2.1% for placebo.
Even more striking, 83% of participants receiving 12 mg lost at least 15% of their starting body weight.
That study was one of the first major signals that retatrutide could become a serious player in obesity medicine.
Then came TRIUMPH 1.
This is the study everybody interested in Retatrutide needs to know.
TRIUMPH 1 was Lilly’s pivotal Phase 3 study evaluating Retatrutide in adults with obesity or overweight plus at least one weight related complication who did not have diabetes.
At 80 weeks, participants receiving:
At the highest dose, that represented an average loss of approximately 70.3 pounds.
And 45.3% of participants receiving 12 mg achieved at least 30% weight loss.
Stop and think about that.
Nearly half of participants in that group lost at least 30% of their starting body weight.
Participants entering an extension with a baseline BMI of at least 35 continued treatment to 104 weeks. At the highest dose, average weight reduction reached approximately 30.3%, or 85 pounds.
These are group averages from a controlled clinical trial.
They do not mean everyone taking Retatrutide will lose 28%, 30%, or any particular amount of weight.
But they explain why Retatrutide has attracted so much attention.
This could become one of the most important comparisons in obesity medicine.
Lilly is conducting TRIUMPH 5, a Phase 3 randomized double blind trial directly comparing retatrutide against tirzepatide in approximately 800 adults with obesity.
The study began in November 2024 and is currently active but no longer recruiting. ClinicalTrials.gov lists estimated primary completion in December 2026.
Why is this so interesting?
Because we’re essentially comparing:
Tirzepatide = GLP 1 + GIP
versus
Retatrutide = GLP 1 + GIP + glucagon.
That means TRIUMPH 5 may help answer an enormous question:
Does adding glucagon receptor activation produce a meaningful advantage over tirzepatide?
As of August 2026, we don’t have that answer.
And that’s exactly why you should be skeptical whenever someone online tells you that retatrutide has already been “proven better than tirzepatide.”
We need the head to head results.
No.
As of August 2026, retatrutide remains an investigational drug.
That distinction is extremely important.
The retatrutide producing these Phase 2 and Phase 3 clinical trial results is Lilly’s investigational pharmaceutical product studied under controlled clinical trial conditions.
Research products sold online claiming to contain retatrutide should not automatically be assumed to be equivalent to Lilly’s investigational drug in purity, manufacturing, sterility, potency or clinical performance.
The FDA also warns that unapproved drugs have not undergone FDA review for safety, effectiveness, consistent manufacturing quality or complete labeling.
Because retatrutide isn’t approved yet, there is no finalized FDA prescribing label defining an “ideal candidate.”
The better question is:
Who has Lilly actually studied?
The Phase 2 obesity trial enrolled adults with a BMI of 30 or greater, or a BMI between 27 and under 30 with at least one weight related condition.
TRIUMPH 1 similarly studied adults with obesity or overweight and at least one weight related complication without diabetes.
So if you’re a relatively lean 48 year old guy looking to drop the final five pounds from your abs, you should not look at these studies and assume they were conducted on people like you.
That’s one of the biggest mistakes people make when interpreting research.
Always ask:
Who was actually studied?
Retatrutide’s most commonly reported adverse effects have involved the gastrointestinal system.
In the Phase 2 obesity trial, gastrointestinal adverse events were the most common side effects. They were generally mild to moderate, occurred more frequently at higher doses and were partially reduced by beginning with a lower starting dose. Researchers also observed dose dependent increases in heart rate that peaked around week 24 and then declined.
Common gastrointestinal problems with this type of therapy can include nausea, diarrhea, vomiting, constipation and decreased appetite.
This matters for men over 40 because “I don’t feel hungry” isn’t automatically a benefit if appetite suppression becomes so strong that you consistently under eat protein, essential nutrients and total calories.
And side effects aren’t merely an inconvenience.
They are one reason pharmaceutical clinical trials use structured dose escalation rather than immediately starting participants at the highest dose.
This deserves its own section.
Whenever someone loses a substantial amount of body weight, that weight isn’t necessarily 100% body fat.
Some lean tissue can be lost too.
For a man in his 40s, 50s, 60s or beyond, that matters enormously.
Muscle helps support strength, glucose disposal, physical function, bone health, metabolic health and independence as you age.
So my goal isn’t:
Maximum weight loss at all costs.
It’s:
Maximum FAT loss while protecting as much MUSCLE as possible.
If GLP 1 based or next generation obesity therapies eventually become part of your medically supervised strategy, resistance training, sufficient dietary protein, intelligent nutrition and monitoring strength and body composition become even more important.
Don’t just ask:
“How much weight did I lose?”
Ask:
“What did I lose?”
Because retatrutide remains investigational, we should not invent a finalized list of FDA contraindications that doesn’t yet exist.
Instead, look at this as a medical screening question.
Anyone considering participation in a retatrutide clinical trial or, eventually, treatment if the drug becomes approved would need individual medical assessment based on health history, medications and risk factors.
Particular caution is appropriate around gastrointestinal disease, pancreatitis history and other conditions relevant to incretin based medications. Pregnancy is also obviously outside the intended population for an article focused on men over 40.
The important takeaway is simple:
Being overweight doesn’t automatically make someone an appropriate candidate for every weight loss medication.
Here we need to make a very important distinction.
Lilly’s retatrutide clinical trials are pharmaceutical studies. Lilly’s Phase 2 obesity study administered retatrutide as a once weekly subcutaneous injection using defined pharmaceutical trial protocols.
Research peptide vendors may instead provide lyophilized vials that require reconstitution. Those products and instructions should not be confused with Lilly’s investigational pharmaceutical product.
The older peptide reference sheet currently available in my source materials lists a 10 mg research vial reconstituted with 2 mL bacteriostatic water, but it also lists a dosing schedule that is completely different from Lilly’s clinical trial program.
For that reason, I am not going to present the vendor protocol as though it were a medically validated retatrutide treatment protocol.
That’s exactly the distinction Peptide Class is designed to teach.
For education only, concentration math works like this.
If a research vial contains 10 mg in 2 mL after reconstitution, the concentration is:
5 mg per mL.
On a U100 insulin syringe, 1 mL equals 100 units.
That means each 10 syringe units represents 0.5 mg at that specific concentration.
The source sheet itself gives the same 10 mg vial, 2 mL reconstitution and 10 unit/0.5 mg relationship.
This calculation is included to explain how concentration works. It is not a recommendation to inject retatrutide, nor does it establish an appropriate human dose.
Once you change either vial strength or the amount of diluent, the unit calculation changes too.
This is one section where I want to do things differently from most peptide websites.
Rather than giving you one number and calling it the “retatrutide dose,” let’s look at what researchers actually did.
In Lilly’s published Phase 2 obesity trial, participants received 1 mg, 4 mg, 8 mg or 12 mg once weekly, with several higher dose groups beginning at either 2 mg or 4 mg rather than immediately receiving the target dose. The gastrointestinal side effects were dose related, and starting lower partially mitigated them.
The newer TRIUMPH 1 Phase 3 program evaluated maintenance doses including 4 mg, 9 mg and 12 mg, again using structured escalation rather than simply beginning participants at the maximum dose.
Compare that with the older research peptide cheat sheet in my materials, which lists a 0.5 mg amount three times weekly.
Those are not the same protocol.
And there is currently no reason to pretend they are.
For Peptide Class, when vendor research protocols conflict with controlled pharmaceutical trials, I’m going to show you the difference rather than quietly blending them together.
Lilly is developing retatrutide as a once weekly treatment.
The Phase 2 obesity study administered retatrutide subcutaneously once weekly for 48 weeks.
Lilly’s ongoing cardiovascular and kidney outcomes study also describes retatrutide as once weekly.
This is another reason I would not describe three times weekly research vendor schedules as though they’re Lilly’s clinically studied protocol.
I don’t think “cycle duration” is the right terminology for retatrutide.
This isn’t being developed like an eight week bodybuilding peptide cycle.
The Phase 2 obesity study lasted 48 weeks.
TRIUMPH 1 assessed its primary weight outcome at 80 weeks, and a prespecified extension followed some participants through 104 weeks.
TRIUMPH 5, the head to head comparison with tirzepatide, is designed to last approximately 89 weeks.
That tells us something important.
Obesity is a chronic disease, and Lilly is studying retatrutide as a long term metabolic therapy, not as a quick “fat loss cycle.”
You’ll find plenty of people online talking about stacking retatrutide with other compounds.
That doesn’t mean those combinations have been proven safe or superior.
I would be particularly cautious about combining retatrutide with other GLP 1, GIP or appetite suppressing compounds without medical supervision because overlapping mechanisms could potentially increase adverse effects without providing a proven additional benefit.
There may eventually be legitimate research into combination therapies, but until we have controlled human evidence, “people online stack these together” isn’t sufficient evidence for me to call something an effective protocol.
Here’s the simplest explanation.
Semaglutide activates GLP 1.
Tirzepatide activates GLP 1 + GIP.
Retatrutide activates GLP 1 + GIP + glucagon.
You could think of them as:
Single → Dual → Triple.
But don’t make the mistake of assuming that more receptors automatically means a better medication for every person.
The real questions are effectiveness, tolerability, long term safety, health outcomes and which treatment is appropriate for a particular patient.
That’s why TRIUMPH 5 is so important: instead of trying to compare unrelated trials, researchers are directly comparing retatrutide against tirzepatide in the same Phase 3 study.
Is retatrutide a GLP 1?
Yes, but that’s only part of the story. Retatrutide activates the GLP 1 receptor plus GIP and glucagon receptors, making it a triple receptor agonist.
Is retatrutide the same as tirzepatide?
No. Tirzepatide targets GIP and GLP 1 receptors, while retatrutide adds glucagon receptor activation as a third pathway.
How much weight did people lose with retatrutide?
In TRIUMPH 1, participants receiving 12 mg averaged 28.3% weight reduction at 80 weeks, while those receiving 4 mg averaged 19.0%. Participants with BMI of at least 35 who entered the extension achieved up to approximately 30% average reduction at 104 weeks.
Does retatrutide burn fat or just suppress appetite?
Its mechanism goes beyond appetite. GLP 1 and GIP influence appetite and metabolic regulation, while glucagon receptor activation adds effects related to energy and lipid metabolism. However, describing retatrutide as simply “burning fat” oversimplifies a complex drug.
Is retatrutide better than tirzepatide?
We don’t know yet.
TRIUMPH 5 is directly comparing the two in approximately 800 adults with obesity, with estimated study completion in December 2026. Until those results are available, claims that retatrutide has definitively beaten tirzepatide head to head are premature.
Is retatrutide FDA approved?
No. As of August 2026, retatrutide remains investigational.
How often is retatrutide administered in Lilly’s studies?
Once weekly. That is the frequency used in the published Phase 2 obesity trial and Lilly’s current clinical development program.
Does retatrutide help blood sugar?
Yes, human research has demonstrated meaningful effects on glycemic control, including Phase 2 research in adults with type 2 diabetes. However, retatrutide remains investigational and is not currently an approved diabetes medication.
What is TRIUMPH 1?
TRIUMPH 1 is Lilly’s pivotal Phase 3 obesity trial of retatrutide. The highest studied dose produced an average 28.3% weight reduction at 80 weeks.
What is TRIUMPH 5?
TRIUMPH 5 is Lilly’s ongoing Phase 3 head to head trial comparing retatrutide directly with tirzepatide in adults with obesity. Approximately 800 participants are enrolled, and estimated completion is December 2026.
Can retatrutide cause muscle loss?
Substantial weight loss can include some loss of lean tissue, which is why men over 40 should think beyond the bathroom scale. Preserving muscle through resistance training, adequate protein and appropriate nutrition should remain an important part of any medically supervised weight loss strategy.
When could retatrutide become available?
Retatrutide still has to complete the regulatory process. Clinical success does not guarantee FDA approval, so I would avoid promising a specific date until regulators actually make that decision.
Absolutely.
Retatrutide is one of the most exciting investigational metabolic drugs I’ve researched.
But excitement and evidence need to stay in the proper order.
The Phase 2 results were impressive.
The Phase 3 TRIUMPH 1 results are even more impressive.
And the upcoming head to head comparison against tirzepatide could answer another enormous question.
But retatrutide remains investigational.
And I don’t want you looking at a 28.3% average weight reduction and thinking you’ve found a magic injection.
You haven’t.
For men over 40, 50, 60 and beyond, the goal isn’t simply to become smaller.
The goal is to become:
And to protect the muscle you’ve spent decades building.
Peptides and metabolic medications don’t replace the foundation.
They’re tools.
My goal with Peptide Class is to continue researching those tools, follow the human evidence as it develops and help you understand the difference between science, promising research, personal experience and marketing hype.
The primary scientific paper I recommend starting with is Jastreboff and colleagues’ 2023 randomized Phase 2 obesity trial published in the New England Journal of Medicine. It established the major early human evidence for retatrutide and reported up to 24.2% average weight reduction at 48 weeks in the 12 mg group.
Lilly’s 2026 TRIUMPH 1 Phase 3 results provide the newest major obesity data, including the 28.3% average weight reduction at 80 weeks with 12 mg and results from the 104 week extension.
Rosenstock and colleagues’ Phase 2 trial in The Lancet provides important human evidence regarding retatrutide in adults with type 2 diabetes.
ClinicalTrials.gov provides the current study record for TRIUMPH 5 (NCT06662383), the Phase 3 head to head comparison of retatrutide and tirzepatide.
ClinicalTrials.gov also provides the current record for TRIUMPH Outcomes (NCT06383390), which is examining cardiovascular and kidney outcomes in adults living with obesity.
Related Peptide Class Articles
As we build out the series, I recommend internally linking this guide to:
Top 5 Peptides for Fat Loss, Visceral Fat & Metabolic Health After 40
Semaglutide for Men Over 40: Complete Guide
Tirzepatide for Men Over 40: Complete Guide
Retatrutide vs Tirzepatide: What’s the Difference?
Retatrutide vs Semaglutide
Tesamorelin and Visceral Fat After 40
MOTS c for Men Over 40
How to Protect Muscle While Losing Weight on GLP 1 Medications
